Rethinking a drug treatment failure on a traditional ALS target

Research output: Contribution to journalArticle

Abstract

In a recent issue of Experimental Neurology, Boston-Hewes and colleagues used an assay of glutamate transport to screen 1040 FDA approved drugs in an attempt to identify compounds that would increase glutamate transport, a central function of astrocytes, and a potential biological target for neuroprotection for a variety of neurological disorders. They identified the compound nordihydroguaiaretic acid (NDGA) as a particularly good candidate for inducing glutamate transport. Pharmacological increases in glutamate transport could have a number of potential applications to diseases of the nervous system where glutamate excitotoxicity is thought to be a contributing factor to pathogenesis including Amyotrophic Lateral Sclerosis, Alzheimer's disease, Parkinson's disease, stroke, and epilepsy among others. They chose to test this compound in a model of Amyotrophic Lateral Sclerosis (ALS)-the SOD1G93A mouse. In both human ALS and rodent models of the disease, glutamate excitotoxicity and abnormalities in glutamate transporter biology more specifically, have been implicated in ALS disease propagation. Interestingly, while the authors nicely demonstrate that NDGA has a biological effect on glutamate transport in normal (wild type) central nervous system tissues both in vitro and in vivo, it was the somewhat unexpected (and often overlooked) findings in the ALS mouse model that makes this manuscript notable and suggests that rethinking translational approaches to drug therapies in ALS may be on the horizon.

Original languageEnglish (US)
Pages (from-to)254-257
Number of pages4
JournalExperimental Neurology
Volume216
Issue number2
DOIs
StatePublished - Apr 2009

Fingerprint

Amyotrophic Lateral Sclerosis
Treatment Failure
Glutamic Acid
Pharmaceutical Preparations
Masoprocol
Nervous System Diseases
Rodent Diseases
Amino Acid Transport System X-AG
Nerve Tissue
Neurology
Astrocytes
Parkinson Disease
Epilepsy
Alzheimer Disease
Central Nervous System
Stroke
Pharmacology
Drug Therapy

Keywords

  • ALS
  • Drug trial
  • Glutamate
  • Glutamate transport
  • Nordihydroguaiaretic acid
  • P-glycoprotein
  • SOD1

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Rethinking a drug treatment failure on a traditional ALS target. / Maragakis, Nicholas J.

In: Experimental Neurology, Vol. 216, No. 2, 04.2009, p. 254-257.

Research output: Contribution to journalArticle

@article{3114fafbaf8d4ab9a8913ffb2b64348c,
title = "Rethinking a drug treatment failure on a traditional ALS target",
abstract = "In a recent issue of Experimental Neurology, Boston-Hewes and colleagues used an assay of glutamate transport to screen 1040 FDA approved drugs in an attempt to identify compounds that would increase glutamate transport, a central function of astrocytes, and a potential biological target for neuroprotection for a variety of neurological disorders. They identified the compound nordihydroguaiaretic acid (NDGA) as a particularly good candidate for inducing glutamate transport. Pharmacological increases in glutamate transport could have a number of potential applications to diseases of the nervous system where glutamate excitotoxicity is thought to be a contributing factor to pathogenesis including Amyotrophic Lateral Sclerosis, Alzheimer's disease, Parkinson's disease, stroke, and epilepsy among others. They chose to test this compound in a model of Amyotrophic Lateral Sclerosis (ALS)-the SOD1G93A mouse. In both human ALS and rodent models of the disease, glutamate excitotoxicity and abnormalities in glutamate transporter biology more specifically, have been implicated in ALS disease propagation. Interestingly, while the authors nicely demonstrate that NDGA has a biological effect on glutamate transport in normal (wild type) central nervous system tissues both in vitro and in vivo, it was the somewhat unexpected (and often overlooked) findings in the ALS mouse model that makes this manuscript notable and suggests that rethinking translational approaches to drug therapies in ALS may be on the horizon.",
keywords = "ALS, Drug trial, Glutamate, Glutamate transport, Nordihydroguaiaretic acid, P-glycoprotein, SOD1",
author = "Maragakis, {Nicholas J}",
year = "2009",
month = "4",
doi = "10.1016/j.expneurol.2008.12.025",
language = "English (US)",
volume = "216",
pages = "254--257",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Rethinking a drug treatment failure on a traditional ALS target

AU - Maragakis, Nicholas J

PY - 2009/4

Y1 - 2009/4

N2 - In a recent issue of Experimental Neurology, Boston-Hewes and colleagues used an assay of glutamate transport to screen 1040 FDA approved drugs in an attempt to identify compounds that would increase glutamate transport, a central function of astrocytes, and a potential biological target for neuroprotection for a variety of neurological disorders. They identified the compound nordihydroguaiaretic acid (NDGA) as a particularly good candidate for inducing glutamate transport. Pharmacological increases in glutamate transport could have a number of potential applications to diseases of the nervous system where glutamate excitotoxicity is thought to be a contributing factor to pathogenesis including Amyotrophic Lateral Sclerosis, Alzheimer's disease, Parkinson's disease, stroke, and epilepsy among others. They chose to test this compound in a model of Amyotrophic Lateral Sclerosis (ALS)-the SOD1G93A mouse. In both human ALS and rodent models of the disease, glutamate excitotoxicity and abnormalities in glutamate transporter biology more specifically, have been implicated in ALS disease propagation. Interestingly, while the authors nicely demonstrate that NDGA has a biological effect on glutamate transport in normal (wild type) central nervous system tissues both in vitro and in vivo, it was the somewhat unexpected (and often overlooked) findings in the ALS mouse model that makes this manuscript notable and suggests that rethinking translational approaches to drug therapies in ALS may be on the horizon.

AB - In a recent issue of Experimental Neurology, Boston-Hewes and colleagues used an assay of glutamate transport to screen 1040 FDA approved drugs in an attempt to identify compounds that would increase glutamate transport, a central function of astrocytes, and a potential biological target for neuroprotection for a variety of neurological disorders. They identified the compound nordihydroguaiaretic acid (NDGA) as a particularly good candidate for inducing glutamate transport. Pharmacological increases in glutamate transport could have a number of potential applications to diseases of the nervous system where glutamate excitotoxicity is thought to be a contributing factor to pathogenesis including Amyotrophic Lateral Sclerosis, Alzheimer's disease, Parkinson's disease, stroke, and epilepsy among others. They chose to test this compound in a model of Amyotrophic Lateral Sclerosis (ALS)-the SOD1G93A mouse. In both human ALS and rodent models of the disease, glutamate excitotoxicity and abnormalities in glutamate transporter biology more specifically, have been implicated in ALS disease propagation. Interestingly, while the authors nicely demonstrate that NDGA has a biological effect on glutamate transport in normal (wild type) central nervous system tissues both in vitro and in vivo, it was the somewhat unexpected (and often overlooked) findings in the ALS mouse model that makes this manuscript notable and suggests that rethinking translational approaches to drug therapies in ALS may be on the horizon.

KW - ALS

KW - Drug trial

KW - Glutamate

KW - Glutamate transport

KW - Nordihydroguaiaretic acid

KW - P-glycoprotein

KW - SOD1

UR - http://www.scopus.com/inward/record.url?scp=62049083766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62049083766&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2008.12.025

DO - 10.1016/j.expneurol.2008.12.025

M3 - Article

C2 - 19309797

AN - SCOPUS:62049083766

VL - 216

SP - 254

EP - 257

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -